Heparin and Low-Molecular-Weight Heparin

This publication has 183 references indexed in Scilit:

• Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies
  American Heart Journal, 2003
• Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction
  Journal of the American College of Cardiology, 2000
• A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
  Journal of Internal Medicine, 1996
• Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormality
  American Heart Journal, 1990
• The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
  The Journal of Clinical Pharmacology, 1988
• Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein Thrombosis
  New England Journal of Medicine, 1986
• Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
  Biochemical and Biophysical Research Communications, 1983
• The effects of phospholipid and factor Va on the inhibition of Factor Xa by antithrombin III
  Biochemical and Biophysical Research Communications, 1979
• Highly active heparin species with multiple binding sites for antithrombin
  Biochemical and Biophysical Research Communications, 1979
• The separation of active and inactive forms of heparin
  Biochemical and Biophysical Research Communications, 1976